Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment.
J Consult Clin Psychol
; 70(4): 887-96, 2002 Aug.
Article
em En
| MEDLINE
| ID: mdl-12182272
ABSTRACT
The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
Base de dados:
MEDLINE
Assunto principal:
Terapia Comportamental
/
Fluoxetina
/
Abandono do Hábito de Fumar
/
Inibidores Seletivos de Recaptação de Serotonina
/
Prevenção do Hábito de Fumar
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Consult Clin Psychol
Ano de publicação:
2002
Tipo de documento:
Article
País de afiliação:
Estados Unidos